An open-label extension of Study M15-741 to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease (NCT04379050)
ABBVIE
This trial is No longer recruiting
Registration number NCT04379050
Program & service
This trial is being run with the Brain service, and as part of the Neurology program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Dr Kelly Bertram
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR